Epivax Oncology
company
About
Epivax Oncology is a providence, RI and NY-based precision cancer immunotherapy company.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $324.98K
- Industries
- Biotechnology,Health Care,Hospital
- Founded date
- Jan 1, 2017
- Number Of Employee
- 1 - 10
- Operating Status
- Active
EpiVax Oncology is a provider of a clinical research and development platform intended to offer various type of precision cancer immunotherapies. The company's platform are based on optimal neo-epitopes selected through its proprietary and validated, in-silico, predictive algorithms, enabling clients to address the unmet medical needs that are inadequately addressed by current cancer therapeutic approaches.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$1.52M
Epivax Oncology has raised a total of
$1.52M
in funding over 2 rounds. Their latest funding was raised on
Jun 12, 2018 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 12, 2018 | Series Unknown | $1.20M | 2 | — | — | Detail |
| May 18, 2018 | Grant | $324.98K | 1 |
National Institutes of Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
Epivax Oncology is funded by 3 investors.
National Institutes of Health
and Horatio Ventures NYC
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
|
|
— | Series Unknown |
NextWaveBio
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
